Keyphrases
Budesonide
100%
Active Crohn's Disease
100%
Mesalamine
100%
Crohn's Disease Activity Index
18%
Adverse Events
18%
Eudragit
18%
Clinical Remission
18%
Once-daily
18%
Repeated Confidence Intervals
9%
In(III)
9%
Double Dummy
9%
Between-group
9%
Non-inferiority
9%
Daily Regimen
9%
Modified Release
9%
P-15
9%
Other-efficacy
9%
Remission Rate
9%
Randomized Double-blind
9%
Treatment Response
9%
Clinically Meaningful Difference
9%
Pharmacology, Toxicology and Pharmaceutical Science
Budesonide
100%
Aminosalicylic Acid
100%
Crohn's Disease
100%
Disease Activity
18%
Remission
18%
Eudragit
18%
Adverse Event
18%
Modified Release
9%